Biogen Inc.
Biogen Inc. (BIIB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BIIB · as of Jun 8, 2026
Key Statistics
Explore Biogen Inc. Data
biib stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 48 · Buy rate: 58.3%
The BIIB analyst consensus is Buy, based on ratings from 48 Wall Street analysts over the past 3 months. The average 12-month price target is $212.26, representing +8.66% upside from the current price of $195.34.
Competitors & Peers
biib competitorsBIIB
DGX
DXCM
GMAB
INCY
LHStock Performance
Full HistoryAbout Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and F…
what is biogen inc. · biib stock overview · biogen inc. company profile · who is biogen inc. ceo · biib NASDAQ · biogen inc. headquarters · biogen inc. business segments
About Stock Overview & Key Data
Biogen Inc. (BIIB) is a Healthcare company in the Drug Manufacturers - General industry, listed on NASDAQ since Sep 17, 1991. As of the latest trading session, BIIB stock price is $195.34, with a market capitalization of $28.8B. The stock has returned +45.61% over the past 12 months and +10.99% year-to-date.
According to 48 Wall Street analysts, the consensus rating for Biogen Inc. stock is Buy, with an average 12-month price target of $212.26. In fiscal year 2025, Biogen Inc. reported revenue of $9.8B and net income of $1.3B. For detailed data — including Biogen Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Biogen Inc. (BIIB) stock price is $195.34. The stock is traded on NASDAQ under the ticker symbol BIIB. The 52-week range is $121.05 – $205.97.